{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:40:21Z","timestamp":1791463221845,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.cmi.2019.04.018","type":"journal-article","created":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T12:19:40Z","timestamp":1556281180000},"page":"1195-1199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Why don't we have more inhaled antibiotics to treat ventilator-associated pneumonia?"],"prefix":"10.1016","volume":"25","author":[{"given":"D.A.","family":"Sweeney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Kalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2019.04.018_bib1","series-title":"Centers for disease control and prevention. Ventilator-associated event (VAE)","year":"2019"},{"key":"10.1016\/j.cmi.2019.04.018_bib2","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1097\/00003246-200112000-00012","article-title":"Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: a prospective case\u2013control study","volume":"29","author":"Bercault","year":"2001","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2019.04.018_bib3","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1086\/591062","article-title":"Strategies to prevent ventilator-associated pneumonia in acute care hospitals","volume":"29","author":"Coffin","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.cmi.2019.04.018_bib4","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Emerging infections program healthcare-associated I, antimicrobial use prevalence survey T. Multistate point-prevalence survey of health care-associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2019.04.018_bib5","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ajic.2013.12.009","article-title":"The impact of multidrug resistance on outcomes in ventilator-associated pneumonia","volume":"42","author":"Tedja","year":"2014","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.cmi.2019.04.018_bib6","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00134-007-0721-0","article-title":"Excess ICU mortality attributable to ventilator-associated pneumonia: the role of early vs late onset","volume":"33","author":"Valles","year":"2007","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2019.04.018_bib7","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1513\/AnnalsATS.201311-395FR","article-title":"Inhaled antibiotics for lower airway infections","volume":"11","author":"Quon","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.cmi.2019.04.018_bib8","unstructured":"FDA. FDA approves a new antibacterial drug to treat a serious lung disease using a novel pathway to spur innovation. Available at: https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm622048.htm. Accessed 4 January 2019."},{"key":"10.1016\/j.cmi.2019.04.018_bib9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1128\/AAC.34.2.269","article-title":"Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. The Endotracheal Tobramycin Study Group","volume":"34","author":"Brown","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.04.018_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2253-13-45","article-title":"Adjunctive aerosolized colistin for multi-drug resistant gram-negative pneumonia in the critically ill: a retrospective study","volume":"13","author":"Doshi","year":"2013","journal-title":"BMC Anesthesiol"},{"key":"10.1016\/j.cmi.2019.04.018_bib11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1089\/sur.2006.051","article-title":"Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study","volume":"8","author":"Hallal","year":"2007","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.cmi.2019.04.018_bib12","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1086\/657242","article-title":"Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case\u2013control study","volume":"51","author":"Kofteridis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.04.018_bib13","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1469-0691.2009.03040.x","article-title":"Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study","volume":"16","author":"Korbila","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.04.018_bib14","first-page":"76","article-title":"[Administration of tobramycin aerosols in patients with nosocomial pneumonia: a preliminary study]","volume":"29","author":"Le Conte","year":"2000","journal-title":"Presse Med"},{"key":"10.1016\/j.cmi.2019.04.018_bib15","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/CCM.0b013e31817c0f9e","article-title":"Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit","volume":"36","author":"Palmer","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2019.04.018_bib16","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1093\/jac\/dkq360","article-title":"Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria","volume":"65","author":"Rattanaumpawan","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.04.018_bib17","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1378\/chest.13-1018","article-title":"Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria","volume":"144","author":"Tumbarello","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2019.04.018_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciw504","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.04.018_bib19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cmi.2017.04.011","article-title":"Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases","volume":"23","author":"Rello","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.04.018_bib20","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/ALN.0000000000001570","article-title":"Nebulization of antiinfective agents in invasively mechanically ventilated adults: a systematic review and meta-analysis","volume":"126","author":"Sole-Lleonart","year":"2017","journal-title":"Anesthesiology"},{"key":"10.1016\/j.cmi.2019.04.018_bib21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1164\/rccm.201011-1894OC","article-title":"Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa","volume":"184","author":"Lu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2019.04.018_bib22","unstructured":"Bayer. Phase III study with Amikacin Inhale in intubated and mechanically ventilated patients with Gram-negative pneumonia does not meet primary endpoint of superiority. https:\/\/www.prnewswire.com\/news-releases\/phase-iii-study-with-amikacin-inhale-in-intubated-and-mechanically-ventilated-patients-with-gram-negative-pneumonia-does-not-meet-primary-endpoint-of-superiority-300561095.html."},{"key":"10.1016\/j.cmi.2019.04.018_bib23","unstructured":"clinicaltrials.gov. Inhaled amikacin solution BAY41-6551 as adjunctive therapy in the treatment of Gram-negative pneumonia (INHALE 1). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01799993."},{"key":"10.1016\/j.cmi.2019.04.018_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00134-011-2420-0","article-title":"BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia","volume":"38","author":"Niederman","year":"2012","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2019.04.018_bib25","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.chest.2016.11.026","article-title":"A\u00a0randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of gram-negative ventilator-associated pneumonia: IASIS Trial","volume":"151","author":"Kollef","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2019.04.018_bib26","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1086\/657243","article-title":"How soon is now? The urgent need for randomized, controlled trials evaluating treatment of multidrug-resistant bacterial infection","volume":"51","author":"Paterson","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.04.018_bib27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/CPM.0b013e31828fc646","article-title":"Defining antibiotic dosing in lung infections","volume":"20","author":"Jamal","year":"2013","journal-title":"Clin Pulm Med"},{"key":"10.1016\/j.cmi.2019.04.018_bib28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1164\/ajrccm.165.2.2107025","article-title":"Lung tissue concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs","volume":"165","author":"Goldstein","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2019.04.018_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40560-015-0072-9","article-title":"Colistin for lung infection: an update","volume":"3","author":"Gurjar","year":"2015","journal-title":"J\u00a0Intensive Care"},{"key":"10.1016\/j.cmi.2019.04.018_bib30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/cid\/ciu213","article-title":"Colistin and polymyxin B: peas in a pod, or chalk and cheese?","volume":"59","author":"Nation","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.04.018_bib31","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1056\/NEJMc071717","article-title":"Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome","volume":"357","author":"McCoy","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2019.04.018_bib32","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s13054-018-1958-4","article-title":"Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects","volume":"22","author":"Torres","year":"2018","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2019.04.018_bib33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4155\/tde-2017-0102","article-title":"Mesh nebulizers have become the first choice for new nebulized pharmaceutical drug developments","volume":"9","author":"Pritchard","year":"2018","journal-title":"Ther Deliv"},{"key":"10.1016\/j.cmi.2019.04.018_bib34","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/bcpt.12499","article-title":"Efficiency of a new mesh-type nebulizer (NE-SM1 NEPLUS) for intrapulmonary delivery of ipratropium bromide in surgical patients","volume":"118","author":"Lee","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X19301958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X19301958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:23:31Z","timestamp":1761117811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X19301958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1198743X19301958"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2019.04.018","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Why don't we have more inhaled antibiotics to treat ventilator-associated pneumonia?","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2019.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}